Tests PF-08634404 with other cancer medicines in advanced lung cancer
Tests PF-08634404 with other cancer medicines in adults with advanced non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Key facts
- Where
- Mayagüez, Rio Piedras, and San Juan, Puerto RicoSee the 3 sites
- Phase
- Phase 1/2
Where in Puerto Rico
- Pan American Center for Oncology Trials, LLC - MayaguezMayagüez, Puerto RicoTaking people
- Pan American Center for Oncology Trials LLCRio Piedras, Puerto RicoTaking people
- BRCR Global Puerto Rico - Hato ReySan Juan, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07227298EU 2025-523526-40-00
- Record updated
- 8 October 2026
- Original description
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments.Read full original descriptionShow less
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments.
To join in the study, participants must:
* Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body
The study will look at:
* Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors.
The study has different parts, each testing PF-08634404 with a different cancer medicine:
* Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B will test PF-08634404 with a medicine called PF-08046054/SGN-PDL1V
Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Inclusion: Pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC and are not a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy; PD-L1 status available; Part B only: PD-L1 ≥ TPS 1%; Measurable disease based on RECIST v1.1 per investigator; Eastern Cooperative Oncology Group performance status of 0 or 1; Adequate organ function.
Exclusion: Previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC; Previous treatment with immunotherapy (exception is (neo)adjuvant or consolidation anti-PD-(L)1), ADCs containing MMAE payload, systemic anti-angiogenic therapy, or prior radiotherapy >30 Gy to the lung within 6 months of first dose of study intervention; History of another malignancy within 2 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy; Leptomeningeal disease; Active autoimmune diseases requiring systemic treatment within the past 2 years; Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET for which there are available first-line therapies per local standard-of-care (SOC); Known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression.